Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia
Authorized Users Only
2012
Authors
Thomadaki, HellinidaFloros, Konstantinos V.
Pavlović, Sonja
Tošić, Nataša
Gourgiotis, Dimitrios
Colović, Milica
Scorilas, Andreas
Article (Published version)
Metadata
Show full item recordAbstract
Objectives: BCL2L12 is a recently discovered and cloned gene from members of our research team. It is a novel member of the BCL2 gene family, members of which are implicated in different hematological malignancies. In the present study, we investigated and studied the expression profile of BCL2L12 in acute myeloid leukemia (AML). Design and methods: Total RNA was isolated from peripheral blood of 67 AML patients and healthy donors. The expression profile of BCL2L12 was studied using real-time PCR methodology (SYBR Green chemistry). We also evaluated the association of the BCL2L12 mRNA expression level with clinical and pathological disease parameters, as well with disease-free survival (DFS) and overall survival (OS), using the chi-square (chi(2)) test or the Fisher's exact test, where appropriate. Results: Leukemia patients expressing high level of BCL2L12 were 3 times more likely to relapse (p=0.004) or die (p=0.007) than patients with low level of BCL2L12 expression. Additionally, s...tatistically significant relationships were revealed between BCL2L12 expression level and CD117 expression, the presence of splenomegaly and chemotherapy response. Conclusions: Our results suggest that BCL2L12 can be considered as a new independent prognostic and chemotherapy response marker in AML
Keywords:
Real-time PCR / Prognosis / BCL2 family / Apoptosis / AMLSource:
Clinical Biochemistry, 2012, 45, 16-17, 1362-1367Publisher:
- Pergamon-Elsevier Science Ltd, Oxford
Funding / projects:
- Rare Diseases:Molecular Pathophysiology, Diagnostic and Therapeutic Modalities and Social, Ethical and Legal Aspects (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41004)
- European Social Fund and National Resources - (EPEAEK II) PYTHAGORAS II
DOI: 10.1016/j.clinbiochem.2012.06.012
ISSN: 0009-9120
PubMed: 22728012
WoS: 000311064200017
Scopus: 2-s2.0-84868303971
Collections
Institution/Community
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Thomadaki, Hellinida AU - Floros, Konstantinos V. AU - Pavlović, Sonja AU - Tošić, Nataša AU - Gourgiotis, Dimitrios AU - Colović, Milica AU - Scorilas, Andreas PY - 2012 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/611 AB - Objectives: BCL2L12 is a recently discovered and cloned gene from members of our research team. It is a novel member of the BCL2 gene family, members of which are implicated in different hematological malignancies. In the present study, we investigated and studied the expression profile of BCL2L12 in acute myeloid leukemia (AML). Design and methods: Total RNA was isolated from peripheral blood of 67 AML patients and healthy donors. The expression profile of BCL2L12 was studied using real-time PCR methodology (SYBR Green chemistry). We also evaluated the association of the BCL2L12 mRNA expression level with clinical and pathological disease parameters, as well with disease-free survival (DFS) and overall survival (OS), using the chi-square (chi(2)) test or the Fisher's exact test, where appropriate. Results: Leukemia patients expressing high level of BCL2L12 were 3 times more likely to relapse (p=0.004) or die (p=0.007) than patients with low level of BCL2L12 expression. Additionally, statistically significant relationships were revealed between BCL2L12 expression level and CD117 expression, the presence of splenomegaly and chemotherapy response. Conclusions: Our results suggest that BCL2L12 can be considered as a new independent prognostic and chemotherapy response marker in AML PB - Pergamon-Elsevier Science Ltd, Oxford T2 - Clinical Biochemistry T1 - Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia EP - 1367 IS - 16-17 SP - 1362 VL - 45 DO - 10.1016/j.clinbiochem.2012.06.012 ER -
@article{ author = "Thomadaki, Hellinida and Floros, Konstantinos V. and Pavlović, Sonja and Tošić, Nataša and Gourgiotis, Dimitrios and Colović, Milica and Scorilas, Andreas", year = "2012", abstract = "Objectives: BCL2L12 is a recently discovered and cloned gene from members of our research team. It is a novel member of the BCL2 gene family, members of which are implicated in different hematological malignancies. In the present study, we investigated and studied the expression profile of BCL2L12 in acute myeloid leukemia (AML). Design and methods: Total RNA was isolated from peripheral blood of 67 AML patients and healthy donors. The expression profile of BCL2L12 was studied using real-time PCR methodology (SYBR Green chemistry). We also evaluated the association of the BCL2L12 mRNA expression level with clinical and pathological disease parameters, as well with disease-free survival (DFS) and overall survival (OS), using the chi-square (chi(2)) test or the Fisher's exact test, where appropriate. Results: Leukemia patients expressing high level of BCL2L12 were 3 times more likely to relapse (p=0.004) or die (p=0.007) than patients with low level of BCL2L12 expression. Additionally, statistically significant relationships were revealed between BCL2L12 expression level and CD117 expression, the presence of splenomegaly and chemotherapy response. Conclusions: Our results suggest that BCL2L12 can be considered as a new independent prognostic and chemotherapy response marker in AML", publisher = "Pergamon-Elsevier Science Ltd, Oxford", journal = "Clinical Biochemistry", title = "Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia", pages = "1367-1362", number = "16-17", volume = "45", doi = "10.1016/j.clinbiochem.2012.06.012" }
Thomadaki, H., Floros, K. V., Pavlović, S., Tošić, N., Gourgiotis, D., Colović, M.,& Scorilas, A.. (2012). Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia. in Clinical Biochemistry Pergamon-Elsevier Science Ltd, Oxford., 45(16-17), 1362-1367. https://doi.org/10.1016/j.clinbiochem.2012.06.012
Thomadaki H, Floros KV, Pavlović S, Tošić N, Gourgiotis D, Colović M, Scorilas A. Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia. in Clinical Biochemistry. 2012;45(16-17):1362-1367. doi:10.1016/j.clinbiochem.2012.06.012 .
Thomadaki, Hellinida, Floros, Konstantinos V., Pavlović, Sonja, Tošić, Nataša, Gourgiotis, Dimitrios, Colović, Milica, Scorilas, Andreas, "Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia" in Clinical Biochemistry, 45, no. 16-17 (2012):1362-1367, https://doi.org/10.1016/j.clinbiochem.2012.06.012 . .